NEW YORK, Jan 5, 2026, 06:59 ET — Premarket
- Brand Engagement Network shares were up 5.3% in premarket trading, extending Friday’s surge.
- The rally has tracked investor focus on a recently disclosed $250,000 AI engagement-services project tied to a top pharma client.
- Traders are watching for follow-through after the open and for late-March timing around the company’s next quarterly update.
Shares of Brand Engagement Network, Inc (BNAI) rose 5.3% to $3.97 in premarket trading on Monday, extending a sharp late-week rally in the thinly traded AI company.
The move keeps the stock on momentum screens after a burst of buying on Friday, when traders piled into small-cap AI names tied to contract headlines. With limited liquidity, the stock can swing quickly — especially in extended-hours trading outside the regular 9:30 a.m. to 4 p.m. session.
Investors are focused on whether the company’s latest disclosed deal can translate into repeatable revenue. Brand Engagement Network reported $60,120 in revenue for the quarter ended Sept. 30 and said it had cash of about $102,715, according to its most recent quarterly filing.
In a Dec. 29 filing, the company said it entered a services agreement with a global advertising and communications agency to develop a custom AI engagement communication method for an established prescription drug for a top-10 global pharmaceutical client, with both counterparties kept confidential. Chief Executive Tyler Luck said the agreement “reflects BEN’s progression in healthcare.” SEC
The stock closed up 62.5% at $3.77 on Friday after trading as high as $4.25, with about 97.30 million shares changing hands, MarketBeat data showed.
That puts $4.25 in view as a near-term technical level for traders looking for a breakout, after premarket trading pushed the stock back toward last week’s highs. The $2.50 low from Friday’s session offers a recent reference point if momentum fades.
With the opening bell approaching, investors will watch whether volume returns after the weekend and whether the stock can hold early gains once liquidity improves. Any update that clarifies implementation timing or expands the scope of work could reset expectations around follow-on revenue.
But the setup cuts both ways. Execution risk is high in a small, volatile stock, and any delay in deploying the AI solution would push out the start of the monthly license fees the company has flagged for the first quarter.
Related articles: Pharmaceuticals
